311 related articles for article (PubMed ID: 24821582)
21. Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.
Oosterwijk-Wakka JC; Kats-Ugurlu G; Leenders WP; Kiemeney LA; Old LJ; Mulders PF; Oosterwijk E
BJU Int; 2011 Jan; 107(1):118-25. PubMed ID: 20346054
[TBL] [Abstract][Full Text] [Related]
22. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.
Prior C; Perez-Gracia JL; Garcia-Donas J; Rodriguez-Antona C; Guruceaga E; Esteban E; Suarez C; Castellano D; del Alba AG; Lozano MD; Carles J; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Gurpide A; Lopez-Picazo JM; Hernandez AG; Mellado B; Martínez E; Moreno F; Font A; Calvo A
PLoS One; 2014; 9(1):e86263. PubMed ID: 24475095
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
Wang J; Liu L; Qu Y; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J
J Urol; 2016 Nov; 196(5):1363-1370. PubMed ID: 27288695
[TBL] [Abstract][Full Text] [Related]
24. Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib.
Beuselinck B; Jean-Baptiste J; Schöffski P; Couchy G; Meiller C; Rolland F; Allory Y; Joniau S; Verkarre V; Elaidi R; Lerut E; Roskams T; Patard JJ; Oudard S; Méjean A; Lambrechts D; Zucman-Rossi J
BJU Int; 2016 Dec; 118(6):890-901. PubMed ID: 27417418
[TBL] [Abstract][Full Text] [Related]
25. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
Choueiri TK; Cheng S; Qu AQ; Pastorek J; Atkins MB; Signoretti S
Urol Oncol; 2013 Nov; 31(8):1788-93. PubMed ID: 23141780
[TBL] [Abstract][Full Text] [Related]
26. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.
Beuselinck B; Karadimou A; Lambrechts D; Claes B; Wolter P; Couchy G; Berkers J; van Poppel H; Paridaens R; Schöffski P; Méjean A; Verkarre V; Lerut E; Joly F; Lebret T; Gravis G; Deplanque G; Descazeaud A; Leclercq NR; Molinié V; Patard JJ; Teghom C; Elaidi R; Zucman-Rossi J; Oudard S
Acta Oncol; 2014 Jan; 53(1):103-12. PubMed ID: 23421954
[TBL] [Abstract][Full Text] [Related]
27. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Garcia-Donas J; Esteban E; Leandro-García LJ; Castellano DE; González del Alba A; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Mellado B; Martínez E; Moreno F; Font A; Robledo M; Rodríguez-Antona C
Lancet Oncol; 2011 Nov; 12(12):1143-50. PubMed ID: 22015057
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma.
Phuoc NB; Ehara H; Gotoh T; Nakano M; Kamei S; Deguchi T; Hirose Y
Oncol Rep; 2008 Sep; 20(3):525-30. PubMed ID: 18695901
[TBL] [Abstract][Full Text] [Related]
29. Vascular Endothelial Growth Factor Receptor-Targeted Therapy in Succinate Dehydrogenase C Kidney Cancer.
Shuch B; Agochukwu N; Ricketts CJ; Vocke CD; Gautam R; Merino M; Linehan WM; Srinivasan R
J Clin Oncol; 2016 Mar; 34(9):e76-9. PubMed ID: 25024072
[No Abstract] [Full Text] [Related]
30. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
31. Carbonic anhydrase IX is expressed in mesothelioma and metastatic clear cell renal cell carcinoma of the lung.
Ramsey ML; Yuh BJ; Johnson MT; Yeldandi AV; Zynger DL
Virchows Arch; 2012 Jan; 460(1):89-93. PubMed ID: 22143934
[TBL] [Abstract][Full Text] [Related]
32. Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy.
Signoretti S; Regan M; Atkins M
BJU Int; 2008 Jun; 101 Suppl 4():31-5. PubMed ID: 18430120
[No Abstract] [Full Text] [Related]
33. High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.
D' Alterio C; Portella L; Ottaiano A; Rizzo M; Carteni G; Pignata S; Facchini G; Perdona S; Di Lorenzo G; Autorino R; Franco R; La Mura A; Nappi O; Castello G; Scala S
Curr Cancer Drug Targets; 2012 Jul; 12(6):693-702. PubMed ID: 22463589
[TBL] [Abstract][Full Text] [Related]
34. Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib.
Vanmechelen M; Lambrechts D; Van Brussel T; Verbiest A; Couchy G; Schöffski P; Dumez H; Debruyne PR; Lerut E; Machiels JP; Richard V; Albersen M; Verschaeve V; Oudard S; Méjean A; Wolter P; Zucman-Rossi J; Beuselinck B
Clin Genitourin Cancer; 2019 Apr; 17(2):e235-e246. PubMed ID: 30527746
[TBL] [Abstract][Full Text] [Related]
35. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS
Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453
[TBL] [Abstract][Full Text] [Related]
36. Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy.
del Puerto-Nevado L; Rojo F; Zazo S; Caramés C; Rubio G; Vega R; Chamizo C; Casado V; Martínez-Useros J; Rincón R; Rodríguez-Remírez M; Borrero-Palacios A; Cristóbal I; Madoz-Gúrpide J; Aguilera O; García-Foncillas J
Br J Cancer; 2014 May; 110(11):2700-7. PubMed ID: 24786599
[TBL] [Abstract][Full Text] [Related]
37. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.
Kim JJ; Vaziri SA; Rini BI; Elson P; Garcia JA; Wirka R; Dreicer R; Ganapathi MK; Ganapathi R
Cancer; 2012 Apr; 118(7):1946-54. PubMed ID: 21882181
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.
Dornbusch J; Walter M; Gottschalk A; Obaje A; Junker K; Ohlmann CH; Meinhardt M; Zacharis A; Zastrow S; Schoffer O; Grimm MO; Klug SJ; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1171-82. PubMed ID: 26935927
[TBL] [Abstract][Full Text] [Related]
39. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.
Cho D; Signoretti S; Dabora S; Regan M; Seeley A; Mariotti M; Youmans A; Polivy A; Mandato L; McDermott D; Stanbridge E; Atkins M
Clin Genitourin Cancer; 2007 Sep; 5(6):379-85. PubMed ID: 17956710
[TBL] [Abstract][Full Text] [Related]
40. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma.
Choueiri TK; Lim ZD; Hirsch MS; Tamboli P; Jonasch E; McDermott DF; Dal Cin P; Corn P; Vaishampayan U; Heng DY; Tannir NM
Cancer; 2010 Nov; 116(22):5219-25. PubMed ID: 20665500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
